Evotec AG Reports Q1 2025 Earnings and Strategic Progress

Evotec Ag (Adr) ( (EVO) ) has released its Q1 earnings. Here is a breakdown of the information Evotec Ag (Adr) presented to its investors.

Evotec AG is a biotechnology company based in Germany, specializing in drug discovery and development solutions for pharmaceutical and biotechnology companies worldwide. The company operates primarily in the life sciences sector, with a focus on leveraging its scientific expertise and technology platforms to advance innovative therapeutic solutions.

In its latest earnings report for the first quarter of 2025, Evotec AG reported a decrease in group revenues by 4% to €200 million compared to the same period in 2024. Despite this decline, the company highlighted significant progress in its strategic protein degradation partnership with Bristol Myers Squibb and the continued growth momentum of its Just – Evotec Biologics segment.

Key financial metrics revealed that while the Shared R&D segment experienced a 9% revenue decline due to ongoing challenges in the pharma market, Just – Evotec Biologics saw a 10% increase in revenues, driven by expanded collaborations and new customer acquisitions. The adjusted Group EBITDA stood at €3.1 million, down from €7.8 million in the previous year, impacted by decreased revenues and increased SG&A expenses.

Strategically, Evotec AG announced a new strategy focusing on high-growth, high-value segments, simplifying its business model, and fostering operational excellence. This includes leveraging automation and AI in drug discovery and pre-clinical development, as well as enhancing the scalability of Just – Evotec Biologics.

Looking ahead, Evotec AG’s management remains optimistic, confirming its 2025 guidance and 2028 outlook. The company expects group revenues to accelerate compared to 2024, with a targeted compound annual growth rate of 8-12% through 2028, and an adjusted EBITDA margin above 20% by the same year.